Next Article in Journal
Prevalence of Homologous Recombination Deficiency in First-Line PARP Inhibitor Maintenance Clinical Trials and Further Implication of Personalized Treatment in Ovarian Cancer
Next Article in Special Issue
Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma
Previous Article in Journal
Population-Attributable Fractions of Personal Comorbidities for Liver, Gallbladder, and Bile Duct Cancers
Previous Article in Special Issue
The Prognostic Value and Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test in Cutaneous Squamous Cell Carcinoma: Systematic Review and Meta-Analysis
 
 
Review

Article Versions Notes

Cancers 2023, 15(12), 3094; https://doi.org/10.3390/cancers15123094
Action Date Notes Link
article xml file uploaded 7 June 2023 12:21 CEST Original file -
article xml uploaded. 7 June 2023 12:21 CEST Update https://www.mdpi.com/2072-6694/15/12/3094/xml
article pdf uploaded. 7 June 2023 12:22 CEST Version of Record https://www.mdpi.com/2072-6694/15/12/3094/pdf
article html file updated 7 June 2023 12:23 CEST Original file -
article html file updated 20 June 2023 21:08 CEST Update https://www.mdpi.com/2072-6694/15/12/3094/html
Back to TopTop